|
Canada-0-RECUPERATION ไดเรกทอรีที่ บริษัท
|
ข่าว บริษัท :
- 2025 Annual Meeting - The Amyloidosis Forum
This meeting detailed the Amyloidosis Forum working groups' projects to accelerate drug development in AL and ATTR Amyloidosis
- EVENT TEMPLATE - The Amyloidosis Forum
Agenda Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
- Considerations for Novel Endpoint Development in AL Amyloidosis
Advancing Drug Development in AL Amyloidosis: Novel Endpoints and Analyses in Multisystemic Rare Disease Trials The virtual Amyloidosis Forum Meeting was held on October 15th, 2020 This page contains a full recording of the meeting, agenda and brief bios on moderators, speakers and panelists Watch the Meeting Agenda Faculty Moderators […]
- Imaging As Amyloidosis Trial Endpoints - The Amyloidosis Forum
This hybrid in-person and virtual meeting of the Amyloidosis Forum explored the different imaging modalities being used in AL ATTR amyloidosis The discussion sought to identify knowledge gaps impeding their implementation as validated tools that could serve as endpoints adequate for drug approval in interventional clinical trials Participants including clinicians, FDA (DIRM, DCN, DHM), MHRA
- Register - 2025 Amyloidosis Forum Annual Meeting
Register here to attend the 2025 Amyloidosis Forum Annual Meeting on October 22, 2025 from 8:00 AM - 4:30 AM ET
- The Amyloidosis Forum
BEGIN:VCALENDAR VERSION:2 0 PRODID:Amyloidosis Forum BEGIN:VEVENT DTSTART:20241023T120000Z DTEND:20241023T201500Z DTSTAMP:20231214T201419Z SUMMARY:Amyloidosis Forum DESCRIPTION:The next meeting of the Amyloidosis Forum, hosted by the Amyloidosis Research Consortium and the US FDA LOCATION:FDA White Oak Campus UID:55469 END:VEVENT END:VCALENDAR
- Prognostic Factors Working Group - The Amyloidosis Forum
Understanding prognostic factors is central to optimizing clinical trial designs in terms of enrichment, inclusion exclusion criteria, baseline stratification, trial durations, and potential use of external control data These design specifications rely on quantitative understanding of baseline prognostic factors for the trial’s endpoints Combinations of prognostic factors into composite
- Understanding AL Amyloidosis - The Amyloidosis Forum
The inaugural meeting of the Amyloidosis Forum took place in November 2019, in the Great Room at the FDA This meeting established the priorities for the Forum To learn more about the priorities read The Amyloidosis Forum: A public private partnership to advance drug development in AL amyloidosis
- 2025 Amyloidosis Forum Annual Meeting
About the Forum The Amyloidosis Forum, a public private partnership, was launched in 2019 with the goal of bridging the gaps in drug discovery and development in AL and ATTR amyloidosis through multi-stakeholder collaboration
- Anonymous Reporting - The Amyloidosis Forum
Please use this digital form to securely report any harassment or misconduct during Amyloidosis Forum events
|
|